Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 113Urinary Bladder Neoplasms 56Carcinoma, Non-Small-Cell Lung 52Cholangiocarcinoma 33Biliary Tract Neoplasms 32Neoplasm Metastasis 30Ovarian Neoplasms 27Lymphoma, Large B-Cell, Diffuse 26Breast Neoplasms 25Lung Neoplasms 24Neoplasms 23Carcinoma, Transitional Cell 23Triple Negative Breast Neoplasms 22Nasopharyngeal Carcinoma 21Colorectal Neoplasms 20Recurrence 17Non-Muscle Invasive Bladder Neoplasms 16Gallbladder Neoplasms 15Fallopian Tube Neoplasms 15Sarcoma 13Bile Duct Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Hodgkin Disease 10Lymphoma 9Uterine Cervical Neoplasms 8Adenocarcinoma 8Stomach Neoplasms 7Lymphoma, Non-Hodgkin 7Endometrial Neoplasms 7Nasopharyngeal Neoplasms 6

Interventions

isoquercitrin 1apixaban 1Tinzaparin 1PEGPH20 1Gemcitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thromboembolism × Gemcitabine × 1 year × Clear all
NCT02921022 2025-11-26

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

Memorial Sloan Kettering Cancer Center

Phase NA Active not recruiting
110 enrolled
Gastrointestinal

Pancreatic Neoplasms, Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡